Psalti I, Loumaye E, Pensis M, Depreester S, Thomas K
Department of Obstetrics and Gynaecology, University of Louvain, Brussels, Belgium.
Fertil Steril. 1989 Nov;52(5):807-11. doi: 10.1016/s0015-0282(16)61035-x.
A comparison was made between a serum substitute. UltroSer G (Gibco, Ghent, Belgium) (2%) (medium B) and 10% human fetal cord serum (medium A), as regards their ability to support 1-cell and 2-cell mice embryo development in vitro. Sixty percent and 56% of the 1-cell embryos reached the expanded blastocyst stage when cultured in media A and B, respectively. Eighty-four percent and 88% of 2-cell embryos reached the expanded blastocyst stage when cultured in media A and B, respectively. A prospective randomized study was then performed to evaluate this synthetic serum substitute in human in vitro fertilization. Among 141 ovum pick-up (OPU), oocytes retrieved in 74 cases were processed in medium A and oocytes retrieved in 67 others in medium B. In media A and B, the fertilization rate was 67% and 44.3% respectively, and the pregnancy rate/OPU 23% and 9%, respectively. The pregnancy rate/transfer was 28.8% and 12.2% respectively, and the implantation rate/transferred embryo 9.5% and 4.2%. In the human sperm survival assay, the vitality and residual motility after 24 hours of incubation were significantly lower in medium B. In conclusion, UltroSer G successfully sustained the development in vitro of mouse embyros. However in human, it reduced sperm survival, oocyte fertilization, and embryo viability.
对一种血清替代品UltroSer G（比利时根特市Gibco公司生产）（2%）（培养基B）和10%人胎牛血清（培养基A）在体外支持1细胞和2细胞小鼠胚胎发育的能力进行了比较。分别在培养基A和B中培养时，60%和56%的1细胞胚胎发育到扩张囊胚阶段。分别在培养基A和B中培养时，84%和88%的2细胞胚胎发育到扩张囊胚阶段。随后进行了一项前瞻性随机研究，以评估这种合成血清替代品在人类体外受精中的效果。在141例取卵（OPU）中，74例取出的卵母细胞在培养基A中处理，另外67例取出的卵母细胞在培养基B中处理。在培养基A和B中，受精率分别为67%和44.3%，每OPU的妊娠率分别为23%和9%。每次移植的妊娠率分别为28.8%和12.2%，每个移植胚胎的着床率分别为9.5%和4.2%。在人类精子存活试验中，在培养基B中孵育24小时后的活力和残余运动能力显著降低。总之，UltroSer G成功地维持了小鼠胚胎的体外发育。然而在人类中，它降低了精子存活率、卵母细胞受精率和胚胎活力。
